A method for intratumoral continuous infusion of antisense oligodeoxynucleotides

Journal of Pharmaceutical Sciences

Volumn 87, Issue 3, 1998, Pages 387-389

  Walker, T L ^a   DeCruz, E E ^a   Dass, C R ^a   Burton, M A ^a  

^a CHARLES STURT UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE;

ANIMAL MODEL; ARTICLE; CANCER MODEL; CANCER THERAPY; CONTINUOUS INFUSION; DRUG DELIVERY SYSTEM; EXPERIMENTAL MODEL; GENE THERAPY; INTRATUMORAL DRUG ADMINISTRATION; NONHUMAN; ONCOGENE C MYC; OSMOTIC PUMP; RAT; SALIVARY GLAND CARCINOMA;

EID: 0031901713     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js970339s     Document Type: Article

References (13)

1. Rankin, E. M.; Kaye, S. B. Principles of chemotherapy. In Treatment of cancer. Sikora, K., Hainan, K., Eds.; Chapman and Hall Medical: London, 1990.
2. Spencer, C. A.; Groudine, M. Control of c-myc regulation Adv. Cancer Res. 1991, 56, 1-48.
3. Watson, P. H.; Safneck, J. R.; Le K.; Dubik, D.; Shiu, R. P. Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumour and lymph node metastasis. J. Natl. Cancer Inst. 1993, 85, 902-907.
4. Smith, D. R.; Myint, T.; Goh, H. S. Overexpression of c-myc in colorectal carcinoma. Br. J. Cancer 1993, 68, 407-413.
5. Tashiro, H.; Miyazaki K.; Okamura H.; Iwai, A.; Fukumoto M. c-myc overexpression in primary ovarian tumours Intl J. Cancer 1992, 50, 828-833.
6. Ogunbiyi, O. A.; Scholefield, J. H.; Rogers, K.; Sharp, F.; Smith, J. H.; Polacarz, S. V. C-myc expression in oral squamous neoplasia. J Clin Pathol. 1993, 46, 23-27.
7. Walker, T. L.; White, J. D.; Esdale, W. J.; Burton, M. A.; DeCruz, E. E. Cisplatin chemotherapy results in selection of tumour cells with elevated c-myc expression. Br. J. Cancer. 1996, 73, 610-614.
8. Crooke, S. T. Progress in development of antisense drugs. Exp. Opin. Invest. Drugs. 1996, 5 (8), 1047-52.
9. Walker, T. L.; Dass, C. R.; Burton, M. A.; DeCruz, E. E. Status of antisense oligodeoxynucleotides as therapeutic agents. Int. J. Pharm Med. In press.
10. Capozza, R. C. An implantable, self-powered pump for drug delivery use in laboratory animals. In Polymeric Delivery Systems; Kostelnik, I., Robert, J., Eds.; Gordon and Breach Science Publishers: New York, 1978.
11. Hayashi, K; Makino, R.; Kawamura, H.; Arisawa, A.; Yoneda, K. Characterisation of rat c-myc and adjacent regions Nucleic Acids Res. 1987, 35, 6419-6436.
12. Zon, G. Antisense phosphorothioate oligodeoxynucleotides-introductory concepts and possible molecular mechanisms of toxicity. Toxicology Lett. 1995, 82-3, 419-424.
13. Tamamoto, T.; Yamamoto, S.; Kataoka, T.; Tokunaga, T. Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. Antisense Res. Dev. 1994, 4, 119-122.